Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?

• Published in: Biomedicine & pharmacotherapy Vol. 162; p. 114367
• Main Authors: Hashemian, Seyed Mohammad Reza, Sheida, Amirhossein, Taghizadieh, Mohammad, Memar, Mohammad Yousef, Hamblin, Michael R., Bannazadeh Baghi, Hossein, Sadri Nahand, Javid, Asemi, Zatollah, Mirzaei, Hamed
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.06.2023; The Authors. Published by Elsevier Masson SAS
• Subjects: 3 C-like protease; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; HIV Protease Inhibitors; Humans; Nirmatrelvir; Pandemics; Paxlovid; Peptide Hydrolases; Review; Ritonavir; SARS-CoV-2; COVID-19; Paxlovid; SARS-CoV-2; Nirmatrelvir; Ritonavir; 3 C-like protease

Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative regimen is yet available, therefore patients are forced to rely on supportive and nonspecific therapies. Some SARS-CoV-2 proteins, like the 3 C-like protease (3CLpro) or the major protease (Mpro), have been ide...